Here’s what you need to know:
1. PixarBio advertises NeuroRelease as a “non-addictive and non-opiate treatment of pain,” meant to replace morphine usage in surgical patients.
2. NeuroRelease affects a patient’s sensory signals, rather than locomotion nerve fibers, to facilitate quick transition to physical therapy.
3. The company hopes to receive FDA approval for their 14-day postoperative pain treatment in 2018. The company also plans to offer four to eight hour, three day, seven day and 90 day pain treatments.
More articles on anesthesia:
White House promotes initiatives for Prescription Opioid and Heroin Epidemic Awareness Week: 5 notes
AANA stands in support of Prescription Opioid and Heroin Epidemic Awareness Week: 3 notes
NorthStar Anesthesia selects new EMR solution: 3 notes on Anesthesia Touch
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.